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Abstract
Soluble IgE receptors are potential in vivo modulators of IgE-mediated immune responses and are thus important for our
basic understanding of allergic responses. We here characterize a novel soluble version of the IgE-binding alpha-chain of Fc-
epsilon-RI (sFceRI), the high affinity receptor for IgE. sFceRI immunoprecipitates as a protein of ,40 kDa and contains an
intact IgE-binding site. In human serum, sFceRI is found as a soluble free IgE receptor as well as a complex with IgE. Using a
newly established ELISA, we show that serum sFceRI levels correlate with serum IgE in patients with elevated IgE. We also
show that serum of individuals with normal IgE levels can be found to contain high levels of sFceRI. After IgE-antigen-
mediated crosslinking of surface FceRI, we detect sFceRI in the exosome-depleted, soluble fraction of cell culture
supernatants. We further show that sFceRI can block binding of IgE to FceRI expressed at the cell surface. In summary, we
here describe the alpha-chain of FceRI as a circulating soluble IgE receptor isoform in human serum.
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Introduction
Allergic patients are commonly characterized by high serum
IgE and high IgE-receptor expression on effector cells of the innate
and adaptive immune system [1,2]. In humans, three different
IgE-receptors have been described: CD23, galectin-3 and FceRI
[1,2]. CD23, also known as FceRII, is a low affinity IgE receptor
and the classical IgE receptor on B cells. Galectin-3, formerly
known as epsilon binding protein (eBP), is another low affinity IgE
receptor; its role in allergy is rather poorly defined [3,4]. FceRI,
the high-affinity receptor for IgE, induces activation of mast cells
and basophils via IgE-antigen complexes during the acute phase of
an allergic response [5,6]. In rodents, FceRI is constitutively
expressed on the surface of basophils and mast cells as a tetrameric
receptor composed of the ligand-binding alpha-chain, one beta-
chain and a pair of disulphide-linked gamma-chains. Humans can
express a trimeric version of FceRI lacking the beta-chain on
eosinophils and antigen presenting cells, such as dendritic cells and
Langerhans cells [6,7]. Additionally, expression of FceRI on
bronchial and intestinal epithelial cells was described in humans
[8,9]. Serum IgE binding stabilizes surface FceRI leading to the
upregulation of receptor levels in allergic patients [10,11,12].
In addition to the transmembrane forms, CD23 and galectin-3
are found as soluble proteins in human serum. Soluble CD23
(sCD23) is a modulator of IgE responses in vivo and is generated by
cleavage of membrane CD23 from the surface of B-cells [13].
sCD23 has been demonstrated to enhance IgE production
[14,15,16] and several reports show that high serum levels of
sCD23 correlate directly with the severity of allergy and asthma
[17]. Along this line, successful immune therapy is accompanied
by a drop in sCD23 levels in the serum of allergic patients [18].
The role of sCD23 in modulating IgE production and its potential
for monitoring allergic responses has been discussed for more than
two decades [13,19,20]. However, sCD23 is currently approved as
a prognostic parameter only for B-cell chronic lymphocytic
leukemia [21,22,23]. Interestingly, soluble galactin-3 is also a
common marker for tumor burden [4,24]. Why the production of
these soluble IgE receptors is induced during malignant diseases is
an interesting scientific question that has yet to be resolved. Thus,
our limited understanding of the in vivo role of sCD23 and soluble
galectin-3 highlights the need for continued research on soluble
factors that modulate serum IgE responses in the context of an
allergic response.
FceRI is an activating immune receptor of the immunoglobulin
superfamily, which includes the Fc receptors CD16, CD32, CD64
and CD89 [6,25,26]. FceRI shares key structural characteristics
and signaling features with these Fc receptors. For most IgE, IgG
and IgA Fc receptors, soluble isoforms are found in humans.
FceRI, however, has so far not been reported as a soluble IgE
receptor in human serum [1,6].
Here we describe a soluble form of the FceRI alpha-chain
(sFceRI). In human serum, this sFceRI is found as both a free form
and bound to its ligand IgE. We show that IgE-mediated cell
activation induces the release of sFceRI in vitro and that the soluble
PLoS ONE | www.plosone.org 1 April 2011 | Volume 6 | Issue 4 | e19098form of the receptor can inhibit binding of IgE to FceRI at the cell
surface.
Results
Detection of a soluble form of FceRI alpha (sFceRI) in
human serum
To give a definitive answer whether a soluble form of the alpha
chain of FceRI exists in humans, we performed immunoprecip-
itation experiments to isolate this protein from serum. Sera from
patients with normal IgE levels and elevated IgE were run over
IgE-columns. Eluates from these columns were analyzed with the
FceRI alpha-chain specific mAb 19-1 by Western blot [12]. The
IgE used for these precipitation is commonly used for detection of
FceRI [12,27] and has a chimeric immunoglobulin containing the
human IgE heavy chain and a murine Fab-anti NP fragment
(referred to as cIgE from here on). Columns were prepared by
coupling cIgE to NP sepharose. 10 ml serum was run over a
gravity column packed with 0.5 ml beads. Figure 1A shows a
representative positive (right lane) and a negative serum (left lane).
A soluble form of FceRI-alpha (sFceRI) was precipitated as a
protein of ,40 kDa (Figure 1A). The higher molecular weight
bands of the Western blot shown in Figure 1A ($130 kDa) are a
result of cross-reactivity of the secondary anti-mouse antibody used
for immunoblotting and the precipitating cIgE. Only the low-
molecular weight protein from the serum precipitate is recognized
specifically by the anti-FceRI alpha-chain specific mAb 19-1.
Since this antibody recognizes the IgE binding epitope of FceRI
alpha [12,28], these data show a soluble non-IgE bound form of
the receptor in human serum. When the mAb 19-1 was replaced
with an isotype control antibody, the sFceRI band was no longer
detected (data not shown). Individuals with normal to moderately
elevated IgE levels tested strongest positive in the immunoprecip-
itation assay. In such sera the sFceRI is likely still available for
precipitation, whereas in patients with elevated IgE the soluble
receptor is mainly bound to serum IgE and therefore cannot be
immunoprecipated by the mAb19-1.
To perform a more detailed molecular characterization of
sFceRI, we next compared sFceRI-alpha precipitated from serum
to FceRI-alpha precipitated from the cell surface of MelJuso-ac
cells. As expected for a soluble form, sFceRI has a lower molecular
weight than the surface expressed protein. Unlike transmembrane
FceRI-alpha, which forms a multimeric complex with the
common FcR-gamma chain (also called FceRI-gamma) [1,6],
sFceRI was not associated with FceR-gamma (Figure 1B). This
finding confirms that sFceRI is likely a soluble serum protein that
is distinct from the membrane multimeric form of the receptor
[6,28].
In summary, this set of results show that the Fc-portion of
human IgE can interact with a soluble alpha-chain protein in
serum and that this serum sFceRI does not have the molecular
characteristics of the multimeric membrane-associated FceRI.
Detection of sFceRI in human serum by ELISA
To allow for semi-quantitative analysis of sFceRI levels in
human serum, we next established a sandwich-ELISA system
(schematic model in Figure 2A). For this ELISA, the anti-FceRI-
alpha mAb CRA1 was used as the capture antibody. This mAb
binds the stalk region of the alpha-chain and is expected to capture
a serum alpha-chain without interfering with the IgE-binding
epitope [29]. Levels of serum sFceRI dropped when comparing
pre- and post-immunoprecipitation samples (Figure 2B), confirm-
ing the specificity of our ELISA. As a further control, capture and
detection antibodies were omitted, which consistently resulted in a
loss of sFceRI signal (data not shown). We were also able to detect
sFceRI in plasma with this ELISA, (data not shown). Using a small
collective of atopic pediatric patients (5 boys, 3 girls, mean age
10.3+/22.7 years; detailed patient characteristics are found in
Table S1), we established that this ELISA is a feasible method for
detection of sFceRI in a larger patient set. In summary, this set of
data describes a novel ELISA for the detection of serum sFceRI.
Any conclusions about the clinical relevance of this finding are
however not possible based on the small patient collective.
Serum levels of sFceRI correlate with serum IgE levels in
patients with elevated IgE
Due to the absence of a recombinant sFceRI protein for the
generation of a standard curve, the specific, blanked OD was used
for semi-quantitative analysis of serum sFceRI levels. To
investigate the occurrence of sFceRI and potential associations
Figure 1. A soluble form of the high affinity IgE receptor, FceRI, is found in human serum. A. Immunoprecipitations from a negative (first
lane, Serum 1) and a positive (right lane, Serum 2) serum specimens. Soluble FceRI (sFceRI) was precipitated from serum with IgE-loaded NIP-beads
and eluted with non-reducing Laemmli sample buffer. Eluates were separated on 12% non-reducing SDS-PAGE gels, transferred to PVDF membranes
and probed with anti-FceRI-alpha mAb 19-1 followed by peroxidase (HRP)-conjugated goat-anti-mouse IgG for detection of precipitated a-chain. B.
Comparison of sFceRI from serum (upper left blot) with FceRI precipitated from the cell surface of MelJuso-ac cells (upper right blot). In the low
molecular weight range, blots were re-probed with an anti-FceRI-gamma polyclonal serum. sFceRI does not associate with the gamma chain (lower
panel). Molecular weight is given in kDa.
doi:10.1371/journal.pone.0019098.g001
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cohort of 119 children (56 boys, 63 girls, mean age 10.6+/25.3
years) with a wide range of normal and elevated serum IgE levels.
Patients were categorized based on the specifications given in the
Materials and Methods section into individuals with normal or
elevated IgE. We found a weak correlation between serum IgE
and sFceRI in patients with elevated IgE (n=32, rho=0.291,
p=0.106, Spearman’s rank correlation, Figure 2C). In children
with normal IgE levels, sFceRI was also found, but no correlation
to serum IgE was detected (n=87, rho=0.02, p=0.874, Spear-
man’s rank correlation, Figure 2D). Interestingly, patients with
highest levels of sFceRI did not show elevated serum IgE levels
(Figure 2D). In an independent experiment, we confirmed that
sFceRI itself did not interfere with detection of IgE and vice versa
(data not shown). One limitation of the analyzed patient cohort is
that it does not contain healthy individuals, because truly healthy
children do not undergo upper GI tract endoscopy for diagnostic
purposes. Our patients are controls with regards to the non-
inflamed esophageal tissue, but show clinical symptoms of yet
unclassified nature. For conclusions on the clinical relevance of our
findings it is therefore important to study sFceRI in sera from truly
healthy controls.
sFceRI circulates as a free or an IgE-complexed protein in
human serum
The alpha-chain of FceRI has a high-affinity-binding site for
IgE [6]. It is thus likely that sFceRI exists as a preformed complex
with IgE in human serum. By omitting the IgE incubation step in
our ELISA and detection with the anti-human IgE-HRP
conjugate, our method allowed for the detection of sFceRI-IgE
complexes in serum. Subtracting the signal without the in vitro IgE
incubation step from the signal with the IgE incubation step
allowed us to determine how much sFceRI was complexed to IgE
in vivo. We randomly selected 14 sera that were positive for sFceRI
and found that in human serum, sFceRI is present as both a free
and an IgE-bound protein (Figure 2E).
IgE-antigen-mediated receptor crosslinking induces the
production of sFceRI from an FceRI-expressing cell line
The mechanism of sFceRI production cannot be studied using
primary human cells due to limited acess to patient material. We
thus took advantage of a recently established cell line that allows
studying the function of trimeric FceRI in vitro. This new cell line
model is based on MelJuso cells, which were stably transfected
with FceRI-alpha and FceRI-gamma cDNA. The resulting
MelJuso-ac cells express FceRI-alpha at the cell surface
(Figure 3A) and can bind monomeric IgE (Figure 3B, left FACS
histogram). In line with previous reports, IgE binding to MelJuso-
ac also induces upregulation of surface FceRI-alpha, a key feature
of this FC receptor (Figure 3B, right FACS histogram). Multimeric
FceRI complexes containing FceRI-alpha and FceRI-gamma
subunits can be precipitated from this cell line (Figure 3C) and
receptor activation by crosslinking of FceRI induces efficient
receptor internalization from the cell surface (Figure 3D). All of
these features match the characteristics of trimeric human FceRI
found in the literature [10,11,12]. Thus, we used this cell model to
address whether IgE-mediated activation of cell-surface FceRI
induces the release of the soluble form of the receptor. MelJuso-ac
cells were loaded overnight with hapten-specific cIgE. After
removal of excess cIgE, surface FceRI was activated by cross-
linking the receptor-bound ligand with haptenized antigen. 36 h
after receptor crosslinking, sFceRI was precipitated from culture
Figure 2. Detection of sFceRI in human serum by ELISA. A. Schematic of the ELISA established for the detection of sFceRI. B. ELISA
measurements pre- and post-immunoprecipitation with IgE-loaded NIP-beads confirmed that IgE immunoprecipitation depleted serum of sFceRI. OD,
optical density at 450 nm. C. In children with elevated IgE-levels, levels of sFceRI and total IgE levels correlate. D. In children with normal serum IgE-
levels, sFceRI could be detected, but no correlation with total IgE levels was found. E. sFceRI circulates as a free or an IgE-complexed protein in human
serum. By omitting the IgE-loading step in the ELISA protocol, circulating complexes of IgE and sFceRI were measured. The fraction of free sFceRI was
then calculated as OD(total sFceRI)2OD(IgE- sFceRI complexes)=OD (free sFceRI). Graph displays the 14 patients with the highest OD (total sFceRI)
with an arbitrary cut off of .0.15.
doi:10.1371/journal.pone.0019098.g002
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ting with mAb 19-1 and compared to sFceRI precipitated from
patient serum (Figure 3E). Next, the kinetics of sFceRI release was
studied by harvesting supernatants 4, 8, 24 and 32 h after receptor
crosslinking for analysis by ELISA. Accumulation of sFceRI was
observed only after receptor crosslinking (Figure 3F, left graph).
sFceRI was not detected in supernatants of empty vector-
transfected MelJusoØØ cells that do not express FceRI
(Figure 3F, right graph). To demonstrate that the detected protein
was a soluble form of FceRI and not protein shedded with
exosomes or derived from cell debris, sequential high-speed
ultracentrifugation was performed to deplete the supernatants
from cell debris and exosomes as established by Thery et al. [30].
sFceRI was detected in the exosome-depleted, soluble fraction
after high-speed centrifugation confirming that the detected
protein is a bona fide soluble form of the receptor (Figure 3G).
sFceRI inhibits IgE loading of FceRI at the cell surface in
vitro
Since we detected IgE-sFceRI complexes in serum, we
speculated that sFceRI could interfere with IgE-binding to FceRI
Figure 3. sFceRI is released from a cell line after IgE-antigen-mediated receptor crosslinking. A. Surface FceRIa expression of MelJuso-ac
cells (black histogram) compared to MelJuso cells (filled gray histogram) and isotype control (grey hedged histogram). B. Detection of IgE binding of
MelJuso-ac cells with NP-PE (left overlay) and of increased surface FceRIa expression induced by IgE binding (right overlay). Cells were cultured for
16 h in the presence or absence of cIgE. Black histograms represent cells incubated with cIgE, grey filled histograms are non-cIgE treated cells; isotype
control is shown as gray, hedged histogram. C. Coimmunopreciptiation of FceRI alpha and gamma-chain dimers from MelJuso-ac cells. D. FceRI
internalization induced by antibody-mediated crosslinking. FceRI is shown in red and cell surface membranes were stained with WGA (in green).
Representative images of cells with non-crosslinked FceRI (t=0; left image) and cells 45 min after crosslinking of FceRI (t=45 min; right image). E.
After 36 h of crosslinking, sFceRI can be precipitated from supernatants of activated MelJuso-ac. sFceRI proteins were precipitated with IgE-loaded -
beads, eluted with non-reducing Laemmli sample buffer, separated on 12% non-reducing SDS-PAGE gels, transferred to PVDF membranes, and
probed with anti-FceRI-alpha (mAb 19-1) followed by peroxidase (HRP)-conjugated goat-anti-mouse IgG. F. Kinetics of sFceRI release into culture
supernatants. Supernatants were harvested from MelJuso-ac cell cultures 4, 8, 24 and 32 h after receptor activation (left graph). ELISA measurements
showed an accumulation of sFceRI over time. MelJusoØØ does not produce sFceRI (right graph). G. sFceRI is a soluble protein as it could be detected
in culture supernatants (left lane) and in exosome-depleted culture supernatants (right lane). SN: supernatant; OD: optical density. Molecular weight is
given in kDa.
doi:10.1371/journal.pone.0019098.g003
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could function as a potential modulator of IgE-mediated immune
activation. We tested this hypothesis by loading FceRI-expressing
MelJuso-ac cells with either a mix of cIgE and cell-culture derived
sFceRI or with cIgE diluted with medium control. Cell-bound
cIgE was visualized by flow cytometry with PE-conjugated hapten
NP. sFceRI efficiently blocked binding of cIgE to FceRI expressed
at the cell surface (Figure 4A). Binding of cIgE was blocked in a
dose dependent manner as dilution curves with supernatants from
sFceRI-containing MelJuso-ac cells and control supernatants from
inactivated cells demonstrated (Figure 4B). In summary, these
results show that sFceRI can interfere with binding of IgE to
FceRI at the cell surface of immune cells.
Discussion
We here describe a soluble version of the FceRI-alpha (sFceRI)
chain that circulates in human serum as a free protein or bound to
its natural ligand, IgE. We show that sFceRI is released upon IgE-
antigen-mediated activation of cell surface FceRI in vitro and,
maybe most interestingly, that sFceRI interferes with IgE-binding
to cellular FceRI in vitro. The affinity of IgE with its high affinity
receptor FceRI was defined after crystallization of the ligand with
recombinant version of the alpha chain [31,32]. It is therefore
highly likely that the soluble form in human serum has equally
high affinity as described in the literature.
Commonly, the reagents used to detect transmembrane forms of
FceRI-alpha are directed against the IgE-binding epitope of the
protein. Thus, the identification of sFceRI could easily have been
missed if the detection reagents were not selected carefully. We
here established an ELISA system that uses a monoclonal antibody
directed against the stalk region of the protein [29] to capture
sFceRI and use human IgE combined with anti-IgE for detection
[12]. By omitting the IgE incubation step, this ELISA also allows
for an assessment of the amount of sFceRI that circulates as a
preformed complex with serum IgE.
Several studies with recombinant versions of sFceRI are found
in the literature [33,34]. Since the recombinant sFceRI used as a
tool to interfere with allergic responses and a potential therapeutic
agent, there have been some speculations about a soluble serum
equivalent in the literature [8]. A single report is found in the
literature that described a soluble complex of FceRI in cultures of
human eosinophils [35]. Since the integrity of FceRI complexes
requires the presence of cell membranes [28,36], Seminario et al.
most likely described a version of the receptor that was released in
an exosomal fraction rather than a bona fide soluble protein.
Based on our current understanding of the mechanism of
sFceRI generation, it is fair to assume that serum sFceRI is a
reflection of FceRI activation. In an independent study, we were
able to confirm the observation of Liang et al. [37] showing that
patients can carry substantial amounts of IgE on peripheral blood
cells even in the absence of elevated serum IgE [27]. In summary,
these two studies show that cells in the peripheral blood bind IgE
from the serum and thereby can clear the serum of IgE. These
IgE-loaded cells could be the source of sFceRI when activated.
Figure 4. sFceRI blocks IgE loading of cell surface-expressed FceRI. A. MelJuso-ac were loaded for 30 min on ice with a 1:2 dilution of cIgE in
PBS (left panel) or cIgE in cell culture supernatant containing sFceRI (right panel). B. Serial dilutions of cIgE in a cell culture supernatant containing
sFceRI (black squares) or cIgE in supernatants derived from unstimulated MelJuso-ac that did not contain sFceRI (open triangles; control, open
circles). Cell-bound cIgE was stained with PE-conjugated hapten and measured by flow cytometry. sFceRI prevents cIgE binding to cellular FceRI. MFI:
mean fluorescence intensity.
doi:10.1371/journal.pone.0019098.g004
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supports this hypothesis. On the other hand, IgE-mediated cell
activation could also account for the detection of serum sFceRI in
the absence of high serum IgE levels. Whether patients that have
high sFceRI are protected from allergic diseases will have to be
addressed in detail. Along this line of argument, it is tempting to
speculate that serum sFceRI is a predictive marker for the onset of
allergies that may be detectable even before serum IgE levels are
elevated. We are currently investigating this hypothesis in a
prospective cohort study.
sFceRI is also an excellent candidate for an efficient in vivo
modulator of IgE-mediated responses. While sCD23 has to
trimerize to develop considerable affinity for its ligand [1], sFceRI
can bind IgE with a one-to-one ligand-receptor ratio. Additionally,
the affinity of the FceRI-IgE interaction is exceptionally high and
disruption of a once formed contact requires low pH, which is
physiologically found only in the stomach [1,6,7]. The finding that
receptor crosslinking is required for the production of sFceRI also
hints at a potential negative feedback mechanism. Antigen-IgE-
mediated receptor crosslinking could induce shedding of sFceRI to
remove IgE-binding sites from the cell surface and to terminate
receptor-mediated signaling. In addition, we show here that
sFceRI has the ability to prevent IgE-binding to surface expressed
receptors. Thus the presence of serum sFceRI could inhibit IgE-
loading of effector cells of allergy in vivo.
Our in vitro studies suggest that sFceRI may also prevent IgE-
mediated activation of the immune system by clearing the serum
of IgE in a manner comparable to omalizumab. Omalizumab is a
recombinant humanized monoclonal antibody directed against
serum IgE and currently approved for the treatment of severe
allergic asthma [38,39,40]. Omalizumab also downregulates cell
surface levels of FceRI [41].
In summary we here describe a new soluble form of human
FceRI, the high affinity receptor for IgE (s FceRI), in human
serum. Establishing an improved quantitative ELISA with a
standard protein is now highly important, because such a
quantitative method will allow for an extensive comparative
analysis of serum levels in various patient groups. Such studies will
be of outmost importance to draw conclusions about the clinical
relevance of this new serum IgE receptor. It will be also essential to
gain a better understanding of how endogenous levels of sFceRI
are regulated and how sFceRI is linked to IgE-mediated immune
activation in vivo.
Materials and Methods
Ethics statement
Patient sera used for this study were obtained from an ongoing
prospective cohort study on the role of FceRI in the gastrointes-
tinal tract at Children’s Hospital Boston or had been previously
obtained as part of routine clinical care at the Medical University
of Vienna. The prospective cohort study was approved by the
Investigational Review Board of Children’s Hospital Boston
(Harvard Medical School, Boston, MA) and patients or their legal
guardians provided written informed consent. The retrospective
study of patient sera was approved by the Ethics Committee of
Medical University of Vienna, Vienna, Austria.
Antibodies and reagents
Anti-human FceRI alpha mAb 19-1 was kindly provided by Dr.
J.P. Kinet (Laboratory of Allergy and Immunology, Beth Israel
Deaconess Medical Center, Boston, MA) and used as previously
described [12,28,36]. Anti-human FceRI alpha mAb CRA1 (clone
AER-37) was purchased from eBioscience, San Diego, CA. Anti-
FceRI-gamma polyclonal serum was purchased from Millipore,
Billerica, MA. Chimeric IgE that contains the human Fc domain
and recognizes the haptens 4-hydroxy-3-nitrophenylacetic acid
(NP) and 4-hydroxy-3-iodo-5-nitrophenylacetic acid (NIP) with its
Fab region (cIgE) was derived from Jw 8/5/13 cells (Serotec,
Oxford, UK, kindly provided by Dr. D. Maurer, Department of
Dermatology, Medical University of Vienna, Austria, [12,42]) and
was used for immunoprecipitation of properly folded FceRI-alpha
and for in vitro cell culture experiments. Phycoerythrin (PE)-
conjugated was purchased from Biosearch Technologies, Novato,
CA, and used for flow cytometry analysis. Anti-mouse IgG (Fc
specific, produced in goat; Sigma Aldrich, St. Louis, MO,
#M3534-1 mL) was used for coating of the ELISA plates. High-
IgE human serum (total IgE.2000 kU/L) was purchased from
Bioreclamation, Hicksville, NY to assure the quality control of IgE
used for detection of sFceRI by ELISA. Goat anti-human IgE
HRP conjugated antibody (Caltag, Invitrogen, Carlsbad, CA) was
used as a secondary antibody.
Cell lines and culture conditions
The MelJuso cell line was provided by Hidde L. Ploegh
(WhiteheadInstitute,MIT,Cambridge,MA)andis well-established
for studies on MHC class I and MHC class II trafficking [43].
MelJuso cells that stably express FceRI-alpha and FceRI-gamma
(MelJuso-ac) were generated by viral transduction using a standard
protocol (http://www.stanford.edu/group/nolan/) following the
guidelines of Children’s Hospital Boston. MelJuso cells transfected
with empty vector (MelJusoØØ) and MelJuso-ac cells were
maintained in Dulbecco’s Modified Eagle Medium (DMEM,
Cellgro, MediaTech, Herndon, VA) supplemented with 10% fetal
calf serum (HyClone, Logan, UT), 2 mM glutamine (Cellgro),
100 U/ml penicillin, and 100 mg/ml streptomycin (Gibco BRL,
Gaithersburg, MD). Cells were reselected using hygromycin
(1 mg/ml) and puromycin (1 mg/ml, both Sigma). Jw 8/5/13 cells
[12,42] were used for the production of cIgE and cultured in
RPMI 1640 medium (Gibco, Invitrogen, Grand Island, NY)
supplemented with 10% fetal calf serum (HyClone), 2 mM
glutamine (Cellgro), 100 U/ml penicillin, and 100 mg/ml strepto-
mycin (Gibco BRL).
Patient sera
Sera from adult individuals were tested for the presence of
sFceRI by immunoblot and ELISA. Sera from eight poly-
sensitized, highly atopic children were analyzed for sFceRI by
ELISA. Total serum IgE and allergen-specific IgE were measured
by solid phase immunoassay (Phadia ImmunoCAPH, Pharmacia
Diagnostics, Uppsala, Sweden). Total serum IgE levels are given in
kU/l, specific IgE is given in kUA/l and CAP RAST classes.
Sera from 119 children were obtained from an ongoing
prospective cohort study on the role of FceRI in the gastrointes-
tinal tract. Patients between 1 and 19 years of age scheduled for an
elective esophago-gastro-duodenoscopy at the Division of Gastro-
enterology at Children’s Hospital Boston were randomly invited to
participate. Subjects who used steroids in any form, immunomod-
ulatory drugs, mast cell stabilizer, or leukotriene inhibitor within
the last 3 months, as well as patients with an established diagnosis
of autoimmune, inflammatory, or immunodeficiency disease were
not enrolled. Total serum IgE levels were assessed according to
standard procedures at Children’s Hospital Boston using the
Elecsys IgE II kit (Roche Diagnostics, Mannheim, Germany). IgE
levels are given in kU/l. Expected normal ranges for this assay are
30 kU/l for age 0–3 years, 200 kU/l for 3–10 years, 500 kU/l for
10–14 years, and 200 kU/l for .14 years.
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To target the fully mature form of FceRI alpha as expressed on
the cell surface, we loaded MelJuso-ac cells with cIgE (10 mg/ml
in PBS) before solubilization in lysis buffer (3610
6 cells per ml;
0.5% Brij 96, 20 mM Tris, pH 8.2, 20 mM NaCl, 2 mM EDTA,
0.1% NaN3) containing protease inhibitors (Complete, Roche,
Genentech, South San Francisco, CA) for 30 min on ice.
Immunoprecipitation was next performed with NIP-beads (Sigma)
as previously described [36,42]. Proteins were eluted from beads in
non-reducing Laemmli sample buffer and samples were separated
on 12% non-reducing SDS-PAGE gels, transferred to PVDF
membrane (Pierce, Thermo Fisher Scientific, Rockford, IL) and
probed with anti-FceRI-alpha (mAb 19-1 or CRA1 for reducing
conditions, both 0.5 mg/ml) followed by peroxidase (HRP)-
conjugated goat-anti-mouse IgG for detection of precipitated a-
chain. For immunoprecipitation of sFceRI from serum, 2–5 ml
serum was used. cIgE-loaded NIP columns were also used for
purification of sFceRI from supernatants of MelJuso-ac cells prior
to immunoblotting. Peroxidase activity was detected by Super-
Signal chemiluminescent substrate (Pierce). Accordingly, sFceRI
was precipitated from serum with IgE-coupled beads and
immunoblotting was performed.
For co-immunoprecipitation of FceRI alpha and gamma chains
from MelJuso-ac, cells were loaded overnight with cIgE. Cell
lysates were prepared and incubated with NIP sepharose beads as
described above. FceRI alpha-chain was detected with mAb 19-1,
FceRI gamma-chains with polyclonal rabbit anti-FceRIc antibod-
ies (Upstate).
ELISA for the detection of sFceRI in cell culture
supernatants and serum
To improve sensitivity, wells were first incubated with a goat-
anti-mouse coating antibody (5 mg/ml, Sigma), then with anti-
alpha chain mAb (CRA1 0.5 mg/ml, clone AER-37; eBioscience).
After a blocking step with 10% FCS in PBS, wells were incubated
with sera (1:2 dilution) overnight. After repetitive washing, plate-
bound sFceRI was loaded with IgE (Bioreclamation) and detected
with a goat anti-human IgE-HRP conjugated second step (Caltag).
Rather than using IgE purified from different patient sera, IgE was
purchased to ensure the quality and consistency of this reagent in
our ELISA. Conversion of 3,39,5,59-tetramethyl-benzidine liquid
substrate (TMB, Sigma) was measured at 450 nm. Results are
given as optical density (OD). To control for intra-assay variability,
we included on each plate a positive and a negative control
sample consisting of a pool of three positive or three negative
patients respectively. The levels of circulating IgE-sFceRI
complexes were determined by omitting the IgE-loading step of
the protocol. Levels of free sFceRI were then calculated as follows:
ODtotal sFceRI2ODIgE- sFceRI complexes=OD free sFceRI.
In a subset of patients, sFceRI was measured in plasma and
serum in parallel. For conversion of plasma samples into serum,
BD Serum Separation Tubes (Becton Dickinson) were used
according to the manufacturer’s guidelines.
Production of sFceRI by MelJuso-ac cells and detection in
cell culture supernatants
MelJuso-ac cells were grown to confluence and incubated with
cIgE overnight. Excess cIgE was washed away and ligand-bound
receptor was activated with haptenized antigen (BSA- or OVA-,
1 mg/ml, both from Biosearch Technologies, Novato, CA). Cell
culture supernatants were collected after the indicated time
periods and analyzed for the presence of soluble alpha chain by
ELISA or by immunoprecipitation.
Exosome removal
To remove exosomes from cell culture supernatants, MelJuso-
ac supernatants were treated with a sequence of ultracentrifuga-
tion steps following the protocol published by Thery et al. [30].
Briefly, exosome-free supernatants were obtained by the following
consecutive centrifugations: 300 g for 5 minutes, 1200 g for
20 min, and 10000 g for 30 min, followed by a final centrifugation
step at 110000 g for 1 h.
Flow cytometry analysis
Surface expression of FceRI on MelJuso-ac cells was deter-
mined by staining with the anti-human FceRI alpha mAb CRA1.
IgE binding was tested by culturing MelJuso-ac cells in the
presence or absence of NP-specific cIgE and staining with
phycoerythrin (PE)-conjugated NP (NP-PE; Biosearch Technolo-
gies). For the detection of sFceRI, cells were loaded with either a
mix of cIgE (100 ng/ml) in culture supernatants that contained
sFceRI or supernatants from unstimulated cell cultures for 30 min
on ice. A number of different ratios of cIgE to culture supernatants
was analyzed. FceRI-bound cIgE was stained with NP-PE.
Analysis was performed on a BD FACScan
TM flow cytometer
using CellQuest software for acquisition and data analysis (both
from Becton Dickinson).
Immunofluoresces Microscopy
For FceRI alpha internalization, MelJuso-ac cells were grown
on coverslips (No 1.5), stained first with purified mouse anti-FceRI
alpha CRA1 antibody for 20 min at 37uC and subsequently with
an anti-mouse Alexa Fluor 568 for 45 min at 37uC to induce
receptor crosslinking. Cells were fixed with 4% paraformaldehyde
for 20 min and mounted using Prolong Antifade reagent
(Invitrogen). Both antibodies were diluted in HBSS supplemented
with 10 mM HEPES (Invitrogen) and 5% NuSerum (Invitrogen).
CRA1 was diluted at 1:100 and anti-mouse Alexa Fluor 568 was
diluted at 1:400. Plasma membranes of fixed cells were stained
with Alexa Fluor 647-conjugated wheat germ agglutinin (WGA,
diluted at 1:1000) for 10 min. For time point t=0 cells were fixed
before incubation with anti-mouse Alexa Fluor 568 and WGA. All
incubation steps were carried out in a humidified chamber.
Confocal images were acquired on a Nikon TE2000 inverted
microscope coupled to a Yokogawa spinning disk confocal unit
(Perkin-Elmer Inc.) and an Orca AG scientific-grade cooled CCD
camera (Hamamatsu Photonics K.K.). Slidebook software (Intel-
ligent Imaging Innovations Inc.) was used for image capture,
processing, and analysis.
Statistical Analysis
Correlations between serum IgE and serum sFceRI were
calculated by Spearman’s rank correlation test using SPSS for
Windows (version 16.0, SPSS Inc., Chicago, IL). Spearman’s rank
correlation coefficients are displayed as ‘rho’, a p-value of .0.05
was considered significant.
Supporting Information
Table S1 Serum levels of sFceRI in atopic patients.
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